Objective. Ankylosing spondylitis (AS) is an autoimmune disease that mainly affects the sacroiliac joints and the spine of the lower back. The disease is strongly associated with HLA-B27. Additional genes, singlenucleotide polymorphisms, and molecular components have been identified to be associated with AS, but the exact mechanism that drives disease development remains poorly understood. The killer cell immunoglobulin-like receptors (KIRs) are regulators of cytotoxicity of natural killer cells and T cell subsets and may be relevant in binding to HLA-B27 and the development of AS. We undertook this study to identify possible associations of KIR genotype with susceptibility to AS and disease characteristics including the presence of the HLA-B27 allele, disease severity, and uveitis.
Methods. We performed complete genotyping of the KIR locus in 303 Caucasian AS patients, 119 randomly selected healthy Caucasian controls, and 50 HLA-B27-positive healthy Caucasian controls by multiplex ligationdependent probe amplification assay for detection of gene presence and copy number.
Results. We did not observe a significant association of any specific KIR gene or haplotype with susceptibility to AS or any other clinical manifestation. Disease severity, as measured by fulfilling the criteria for treatment with tumor necrosis factor blocking therapy, was linked to a lower number of genes for the functional variant of KIR3DL1 (P 5 0.007).
Conclusion. Our exploratory study indicates that KIR genes are not a major risk factor for susceptibility to AS. However, the data do suggest a role for KIRs in progression of the disease, whereby KIR3DL1 has a protective effect against the more severe manifestations of AS.
The prevailing subgroup of the axial spondyloarthritides (SpA) is ankylosing spondylitis (AS). It is challenging to diagnose this disease because patients with AS can have a wide variety of clinical features (1) . The main clinical features include inflammation of the sacroiliac joints and the axial skeleton, but extraaxial manifestations such as peripheral arthritis, anterior uveitis, and enthesitis are common in AS patients (2) (3) (4) . Extensive research on genetic associations, pathogenesis, and risk factors in AS has been performed, revealing multiple risk factors for the development of AS. However, in spite of the identification of various genes, molecules, and cells involved, the mechanism underlying the pathogenesis of AS is still poorly understood. Since studies in twins have shown that genetic makeup forms an important risk factor for the development of AS (5-7), several studies were performed to identify the responsible genetic factors. By far the strongest genetic association with AS is the HLA-B27 allele; although 90% of patients carry this allele, it is present in only 7-8% of the healthy Caucasian population (8) . The most common HLA-B27 alleles (B*2702, B*2704, B*2705, and B*2707) are associated with AS, while other alleles (B*2706 and B*2709) are not (9, 10) . However, the risk of disease conferred by the presence of this allele alone is still limited, which suggests that additional genes contribute to disease susceptibility (11) . More recently, genome-wide association studies have uncovered many single-nucleotide polymorphisms (SNPs), within and outside genes, that together explain 24% of the heritability of AS (12) (13) (14) .
HLA class I molecules are the natural ligands of killer cell immunoglobulin-like receptors (KIRs). This family of receptors is an important immune regulator of the cytotoxicity of natural killer (NK) cells and a subset of T cells. It has been suggested that NK cells play an immunomodulatory role in several autoimmune diseases, including AS (15, 16) . As direct binding partners of the key HLA class I molecules associated with AS (and hence regulating NK cell function), KIRs seem to be likely candidates in the pathogenic process that drives AS. The 17 genes that constitute the KIR family are unequally distributed across the population, giving each individual his or her unique KIR gene repertoire through variation in genotype and gene copy number (17) . Depending on its structural makeup, a KIR can communicate with a cell as either an activating or inhibitory signal. There are 6 activating KIRs (KIR-2DS1 through KIR-2DS5 and KIR-3DS1), 9 KIR genes encoding inhibiting receptors (KIR2DL1 through KIR2DL4, KIR2-DL5A, KIR2DL5B, and KIR3DL1 through KIR3DL3), and 2 pseudogenes (KIR2DP1 and KIR3DP1) that are not transcribed into functional proteins.
KIR genes are organized in several haplotypes, as depicted in Figure 1A . The complete KIR locus consists of Figure 1 . Overview of the killer cell immunoglobulin-like receptor (KIR) haplotypes that can occur in the Caucasian population. A, Shown is the KIR gene organization of every possible haplotype at the centromeric (Cent) part and at the telomeric (Tel) part of the KIR locus. The framework genes, depicted in black, are always present in this locus. The genes carry the sequences of 2 or 3 extracellular domains (2D or 3D) and a short (S) or a long (L) cytoplasmic tail, resulting in an activating or inhibiting protein, respectively. Two of the genes carry early stop codons and are considered pseudogenes (P). B, The centromeric and telomeric parts combined form 1 entire KIR locus. Every centromeric region is directly linked to each of the telomeric regions by a 14-kb sequence, resulting in 9 possible KIR loci. C, The telomeric haplotype A (Tel-A) always contains the KIR3DL1 and KIR2DS4 genes. These genes both have variants that do not result in a functional receptor at the cell membrane-KIR3DL1*004 and truncated forms of KIR2DS4 (KIR2DS4 trunc, including the alleles KIR2DS4*003-*010, *012, and *013). The KIR3DL1 alleles that are expressed on the cell membrane (KIR3DL1 expr) are found in combination with either form of KIR2DS4 (KIR2DS4 trunc and the full-length, or wild-type [WT], form of KIR2DS4). However, the KIR3DL1*004 allele is found only in combination with the truncated form of KIR2DS4. a centromeric part and a telomeric part, each of which has 3 possible gene combinations (Cent-A, Cent-B1, and Cent-B2 and Tel-A, Tel-B1, and Tel-B2). In 90% of the Caucasian population, these parts combine into 9 possible KIR haplotype combinations ( Figure 1B) , while the remaining 10% have 1 or 2 different gene combinations due to alternative recombination events (18) (19) (20) .
Every KIR gene has multiple allelic variants, of which some of the encoded proteins are considered nonfunctional due to folding problems after translation into an unstable protein or because of frameshift mutations or SNPs leading to premature termination. The KIR3DL1 and KIR2DS4 genes of the telomeric haplotype A have nonfunctional variants that occur at high carrier frequency in the Caucasian population: KIR3DL1*004 occurs at 15% of alleles, and KIR2DS4-trunc (including the alleles KIR2DS4*003-*010, *012, and *013) occurs at 57% of alleles (17, 18, 21) . KIR3DL1*004 is only found in combination with KIR2DS4 trunc and has never been observed to be in linkage with the full-length form (KIR2DS4 wild type) (18) ( Figure 1C) .
Although previous studies have found that several KIR genes are associated with the development of AS, those studies are few in number and often have a small sample size, and results are not always concordant. Several studies have shown the activating gene KIR3DS1 to be involved in AS, and others have shown the inhibiting gene KIR3DL1 to be either negatively associated with AS or both positively and negatively associated with AS (22) (23) (24) (25) (26) (27) . Some studies have found that KIR3DL1 is negatively associated only in the presence of the allele HLA-Bw4 (23, 24, 28) . One study found the genes KIR2DL1 and KIR2DL5 to be associated with susceptibility to AS (29) , while a second study showed that the gene KIR2DS1 in combination with the allele HLA-C2 was present more often in patients than in controls (24) . A study of KIR3DL2 alleles in 368 patients and of the KIR3DL1 and KIR3DS1 genes in 149 patients did not find any association with disease susceptibility (30) , even in a followup study of KIR3DL1 and KIR3DS1 alleles extended to 242 patients (31) . Most studies were performed in an HLA-B27-positive background, some of the observed associations were only found in the presence of an HLA-B27 or HLA-Bw4 allele (22, 23, (25) (26) (27) 29) , and some of the patient cohorts were of Asian origin (10, 22, 25, 29) while others were of Caucasian origin (26, 30) . These differences in study parameters make it difficult to compare those studies.
Our primary aim was to investigate the KIR gene locus in a large cohort of Caucasian AS patients and controls with a method to determine not only KIR genotypes, but also the individual gene copy number. In addition, we analyzed the relationship between the KIR genotype and important clinical parameters, including age, sex, the presence of HLA-B27, uveitis, and the use of tumor necrosis factor (TNF) blocking therapy, to determine the involvement of KIRs in disease progression of AS.
PATIENTS AND METHODS
Patients. All AS patients fulfilled the modified New York criteria for AS (32) . Patients from several different AS cohorts were included. One group of patients diagnosed as having AS was derived from an early SpA cohort set up at the Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, The Netherlands. The other group consisted of AS patients who were eligible for TNF blocking therapy; this group was derived from cohorts at the Amsterdam Rheumatology and Immunology Center and the VU University Medical Center, Amsterdam, The Netherlands. AS patients were eligible for TNF blocking therapy if they met criteria according to the Dutch consensus statement on the initiation of TNF blocking therapy. These criteria include a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (33) of .4 and failure of disease to respond to treatment with at least 2 different nonsteroidal antiinflammatory drugs used for at least 4 weeks (34). Related individuals were excluded from the study. All AS patients took part in a dense SNP genotyping (ImmunoChip) study (12) ; duplicated samples and those showing cryptic relatedness were assessed by calculating identity by descent and were removed from this study.
Patient characteristics gathered were age at diagnosis of AS, HLA-B27 status, and the presence of extraarticular manifestations such as anterior uveitis, inflammatory bowel disease (IBD), and psoriasis. HLA-B27 status was determined by sequencespecific priming-polymerase chain reaction (PCR). Typing depth occurred at the 2-digit level; primers were based on those described by Olerup and Zino et al (35, 36) . Disease activity at time of inclusion was measured with the BASDAI on a scale of 0-10.
A control cohort representing the Dutch Caucasian population was generated from anonymous healthy blood bank donors at Sanquin Blood Supply Foundation (Amsterdam, The Netherlands). Although relatedness of these healthy controls was not formally excluded, it was highly unlikely. For this study, patients and controls were selected for Caucasian ethnicity. A smaller, HLA-B27-positive control cohort consisted of 50 healthy Caucasian individuals selected from the Sanquin Blood Supply Foundation blood bank repository.
The study was approved by the Institutional Medical Ethics Committee of the Academic Medical Center in Amsterdam and was performed in accordance with the Declaration of Helsinki. All participants provided their written informed consent. KIR genotyping and haplotyping. Using DNAzol reagent (Molecular Research Center) or a QIAamp DNA Blood Mini Kit (Qiagen), genomic DNA was extracted from anticoagulated blood obtained from AS patients or controls, respectively, according to the manufacturers' protocols. KIR genotyping and copy number determination were performed with multiplex ligation-dependent probe amplification as described previously (17) . The KIR2DL5A and KIR2DL5B genes and the expressed and nonexpressed alleles for KIR3DL1 were determined by PCR as described previously (18) .
The genotyping data and copy number determination together allowed us to perform complete haplotyping of the KIR locus in each individual. Only the 9 haplotype combinations depicted in Figure 1B were included in this study. The KIR gene and allele frequencies have been thoroughly studied in Caucasian controls by the same methods, as discussed previously (18) . Because of their low frequency and equal distribution among patients and controls, KIR loci that showed signs of recombination events (5% and 4% of alleles in the telomeric region and 6% and 3% of alleles in the centromeric region of AS patients and the group of unselected healthy controls, respectively) were not considered further.
Statistical analysis. Comparisons of the gene copy number of the KIR genes and the different KIR haplotypes between patients and controls and between patient subgroups were performed using Fisher's exact test. Continuous distribution of age was also studied using linear regression and analysis of variance. Odds ratios (ORs) were calculated using logistic regression. All statistical analyses were performed with IBM SPSS Software version 21. To correct for multiple testing, a Bonferroni correction was applied: 0.05/(7 comparisons 3 7 independent variants) 5 0.0010. P values less than 0.001 were considered significant, while P values between 0.001 and 0.05 were considered suggestive.
Given the sample sizes when comparing AS patients to randomly selected healthy controls, an OR of 2.4-1.5 for AS patients (or 0.4-0.7 for controls) could be found with 80% power for haplotype frequencies ranging from 0.05 to 0.35, assuming a log-additive genetic model and a 2-sided P value of 0.05 (Quanto [37] ). Under these conditions, ORs of 3.2-1.9 (or 0.3-0.5) could be found for AS patients compared to HLA-B27-positive controls. For sex, an OR of 2.8-1.8 (or 0.4-0.6) could be found under the same conditions. Under the same conditions, additional ORs could be found, as follows: for the presence of HLA-B27, 3.5-2.2 (or 0.3-0.5); for age, 2.5-1.6 (or 0.4-0.6); for TNF blocking therapy, 2.7-1.8 (or 0.4-0.6); and, for uveitis, 2.5-1.7 (or 0.4-0.6).
RESULTS
Patient characteristics. A total of 303 Caucasian AS patients (Table 1) , 119 randomly selected healthy Caucasian controls, and 50 HLA-B27-positive healthy Caucasian controls were included. The median age at diagnosis of AS was 31 years (interquartile range 25-40 years). The percentage of males was 75% in the AS patient group, 48% in the randomly selected healthy control group, and 88% in the HLA-B27-positive control group. Of the patients who were genotyped for the HLA-B27 allele, 89% were found to be positive (Table 1) . Clinical data on extraarticular manifestations were available for 93-95% of AS patients, depending on the manifestation; 42% had previously been diagnosed as having either an eye infection or uveitis, and psoriasis and IBD were each present in 7% of the patients. Eighty-nine of 233 AS patients (38%) had been treated at least once or were currently being treated with TNF blocking therapy. Susceptibility in relation to KIR genotype of AS patients and healthy controls. The occurrence of haplotypes for both the centromeric and the telomeric parts of the KIR locus was compared among the patient group and the 2 control groups ( Table 2) . None of the haplotypes had a significantly different distribution among the 3 groups. There was also no difference in the distribution of any of the individual genes (or alleles of KIR3DL1 and KIR2DS4) or their gene copy number between the patients and controls (data not shown). In our study, the contribution of the KIR genotype to the development of AS seemed to be limited.
Disease manifestation and KIR genotype. We studied whether the overrepresentation of male sex or the presence of HLA-B27 was related to a difference in KIR genotype by comparing the distributions of the centromeric and telomeric haplotypes of the KIR locus between male and female AS patients as well as between HLA-B27-positive and HLA-B27-negative AS patients (Table 3) . No significant differences were found between male and female AS patients, either in the KIR haplotype distribution or in the single KIR gene or allele distribution (data not shown).
Other characteristics which varied among AS patients consisted of age at diagnosis and administration of TNF blocking therapy as additional medication. To study KIR genotype based on age at diagnosis, patients were divided into 2 groups: those #30 years old (since the disease generally appears in the second and third decade of life) and those .30 years old. No significant differences in distributions of KIR haplotypes (Table 4) or genes or alleles (data not shown) were found between these 2 age groups. As a control, we studied the continuous distribution of the difference in age groups for each haplotype, gene, and allele, but again, no significant differences were detected (data not shown). When we compared patients who required TNF blocking therapy (n 5 89) with patients who did not (n 5 144), we observed no difference in haplotype distribution (Table 4) .
At the level of the KIR gene and allele distribution, there was a difference in the distribution of the functional KIR3DL1 alleles between patients who received TNF blocking therapy and patients who did not (P 5 0.007) (OR 0.253 for 1 copy versus 0, OR 0.277 for 2 copies versus 0) (Figure 2A ). Patients receiving TNF blocking therapy had fewer functional KIR3DL1 genes. The number of functional KIR3DL1 genes diverged from that in both control groups, both in patients who did and in those who did not receive TNF blocking therapy. The number of nonfunctional KIR3DL1*004 alleles did not differ between patients who received TNF blocking therapy and patients who did not (P 5 0.310) (OR 1.364 for 1 copy versus 0) ( Figure 2B) . Also, the distinct full-length and truncated forms of KIR2DS4, to which KIR3DL1 is strongly linked (18), did not differ significantly between patients who did and patients who did not require TNF blocking therapy ( Figures 2C and D) . We were unable to adjust for followup time after TNF blocking therapy because this information was not available. When comparing the KIR genotypes between patients with and those without uveitis, no differences were observed for the distributions of the KIR haplotypes (Table 4) or genes or alleles (data not shown). Only 21 patients were diagnosed as having psoriasis and 20 as having IBD. We therefore omitted statistical analysis for these specific patients since we deemed these groups too small for an accurate analysis.
DISCUSSION
This is the largest exploratory study involving a detailed analysis of the KIR genotype of Caucasian AS patients and healthy controls (both randomly selected and HLA-B27 positive) performed thus far. While the KIR genotype distribution did not show a large contribution to the risk of developing AS, severity of the disease seemed to be influenced by the KIR genotype. When comparing KIR haplotypes, we did not find any significant difference in KIR haplotype, gene, or allele distribution between patients and controls. In this study, we also included the KIR distribution of patients with clinical features of the disease: age at diagnosis, use of TNF blocking therapy as a marker of disease severity, and uveitis. There was no significant association with age at diagnosis or uveitis. Disease severity was studied by selecting those patients who experienced more severe AS, thus requiring TNF blocking therapy, and comparing them to patients who did not require TNF blocking therapy. Although this difference did not reach significance after correction for In contrast to most previous studies, this study revealed a remarkable lack of association of KIR genes with disease susceptibility. A limitation of our study is that although we did analyze the nonfunctional KIR3DL1*004 allele, we were unable to investigate the distribution of highly and poorly expressed KIR3DL1 alleles in patients and controls. However, no published studies have suggested an association of highly and poorly expressed KIR3DL1 alleles with AS. While other studies have found the genes KIR3DL1 or KIR3DS1 to be distributed differently between AS patients and controls (21-27), we did not observe the same effect. We also did not observe a difference in the KIR3DL1:KIR3DS1 ratio, as reported by Zvyagin et al (26) , either for disease association or for any clinical manifestation including TNF blocking therapy. However, ours is not the only group that did not find any associations between KIR genotype and susceptibility for AS (29, 30) . The differences may result from the smaller sizes of the other patient cohorts, allowing for even small differences to become statistically significant. It may also result from a difference in ethnic background of the study cohorts.
The most important observation in our study is that patients with higher disease activity (who fulfilled criteria for starting TNF blocking therapy) seemed to have fewer functional copies of KIR3DL1 compared to patients who did not need TNF blocking therapy. We emphasize that the statistical difference was not significant after Bonferroni correction, and future studies will need to be conducted to further support our findings. So far, KIR genotype association studies have mainly focused on disease susceptibility rather than disease severity. Instead, our data suggest a possible association between KIR3DL1 and disease severity in AS patients.
Although followup studies will need to show whether KIR3DL1 indeed confers a protective effect against higher AS disease activity, this finding is supported by results from a small study by Mousavi and coworkers on expression of KIR3DL1 and HLA-Bw4 in AS patients. That study showed that expression levels of KIR3DL1 on CD561 lymphocytes were lower in patients than in healthy controls in the presence of HLA-Bw4 iso , the superfamily of HLA alleles that includes the HLA-B27 allele (28) . A gene association study in a small Russian Caucasian HLA-B27-positive cohort indicated that functional KIR3DL1 alleles were less often present in AS patients than in healthy controls, suggesting protective characteristics of the gene against AS disease susceptibility (26). The recurring association of the gene KIR3DL1 with AS is intriguing because HLA-B27 is a natural ligand of the receptor of this gene (38) . Taken together, these data suggest that the role of KIR3DL1 in AS is in disease severity rather than disease susceptibility, as KIR3DL1 seems to play a protective role in the pathogenesis of AS.
The mechanism of AS pathogenesis is still poorly understood. As the disease is highly associated with the presence of HLA-B27, many studies have focused on this molecule. The major clinical symptoms in AS patients arise from structural changes to the bones and joints caused by osteoclastogenesis (4) . TNF levels are elevated in the synovial tissue and serum of SpA patients, and this is known to play a role in osteoclastogenesis and osteoclast recruitment in AS patients (39, 40) . Recent work by Layh-Schmitt and coworkers showed some important findings concerning the mechanism of AS disease pathogenesis. HLA-B27, which is expressed on rat bone marrow-derived monocytes, causes endoplasmic reticulum stress in the cells when stimulated with TNF, leading to increased osteoclast formation, which implicates HLA-B27 in disease pathogenesis (41) .
HLA-B27 is a known ligand for both KIR3DL1 and KIR3DL2 (38) , and the latter gene is a framework gene that is always present in the KIR locus. Therefore, most variation conferred by HLA-B27-interacting KIR protein is expected to result from KIR3DL1. If KIR3DL1 does indeed provide a protective effect against disease severity, as suggested by our data in AS patients fulfilling the criteria for TNF blocking therapy, it is likely that this effect is related to HLA-B27. The fact that we did not see any association of KIR genotype with AS suggests that the KIRs are not a major genetic risk factor for disease susceptibility. However, our data provide the first insight about a possible role for KIRs in the pathogenic processes that drive disease severity and progression in a subgroup of patients.
